EMA Withdrawn: Tizveni (tislelizumab) — BeiGene Ireland Ltd

View source ↗

Summary

The European Medicines Agency has withdrawn the marketing authorization for Tizveni (tislelizumab) by BeiGene Ireland Ltd for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tizveni (tislelizumab)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: BeiGene Ireland Ltd. Decision date: 19/04/2024